In this webinar, the featured speakers will showcase the success of ProPharma’s new Research Consulting Organization (RCO) model, which offers a refreshing approach to drug and device development outsourcing, addressing the challenges faced by smaller and mid-sized innovators with traditional Contract Research Organizations (CROs) that prioritize larger programs. The new RCO delivers a “3-D printed” solution for those sponsor programs that just don’t fit the mold.
The RCO is a new service partner that has emerged in response to the shifting landscape of drug and device development outsourcing. Historically, smaller and mid-sized innovators have found themselves relegated to the end of the queue, piecing together pivotal programs with the CRO’s “C” team. The RCO model offers a new degree of personalization and agility, which is not typically available with rigid CRO models, to meet this need. With smaller rare disease programs representing 40 percent of the industry’s pipeline, the “bigger-the-better” CRO trend has become incongruent with market needs. Traditional CROs are trapped in scale-based economic models, and the “need volume to make the numbers work” mindset, which often results in extraneous services being pushed to help drive appeal and boost margin.
Register for this webinar to discover a personalized approach to drug and device development outsourcing for smaller and mid-sized innovators.
Bryan Katz, Chief Strategy Officer/Head of Corporate Development, ProPharma
Bryan Katz has over 20 years of expertise in the life sciences industry with a focus on solution development, strategy and M&A. Bryan has previously held roles at Abbott, PwC, Quintiles and his most recent role as SVP of Global Solution Development at Syneos Health. During his time at Syneos, he led the design and buildout of new data-driven end-to-end solutions across the industry. Named in 2020 to PM360’s ELITE 100, Bryan has engaged in the pharmaceutical, CRO and life sciences industry through many speaking events and publications, often challenging the status quo and offering creative yet pragmatic solutions.
Bryan’s focuses on working with the ProPharma leadership team directly to develop not only a corporate strategy, but an M&A strategy as well.
Sara Sorrentino, Executive Vice President, Business Development, ProPharma
Sara Sorrentino has 15 years of experience blended between academic research, B2B sales and spent the last 10 years focused on business development and account management within the life sciences industry, specifically focused on the global outsourcing and CRO space.
As ProPharma’s EVP of Global Business Development, Sara partners with pharmaceutical, biotechnology and medical device clients to tackle complex challenges with innovative, creative and efficient solutions. She also serves as a subject-matter expert in the area of clinical research.
David Dobrowski, VP of Clinical Development and Regulatory Affairs, ABK Biomedical
David Dobrowski is a seasoned life sciences executive with over 28 years of pharmaceutical and medical device development experience. David has an extensive record of successful new product approvals across a diverse range of drugs, biologics and devices. Currently, David leads the development of ABK’s new therapy for treatment of liver cancer. Before ABK, David led R&D for North America at Merz, managing a cross functional development team of over 70 people. David also has prior experience presenting to the US Food and Drug Administration (FDA) advisor committees for both drugs and medical devices.
Who Should Attend?
- Leaders and decision-makers of small and midsize biotech companies
- Professionals in clinical development and regulatory affairs
- Individuals who are seeking a more personalized and agile approach to drug and device development outsourcing
What You Will Learn
Attendees will gain insights into:
- What the Research Consulting Organization (RCO) model is and how it works
- A real-life example of how the model works through partnership with ABK Biomedical
For the past 20 years, ProPharma has improved the health and wellness of patients by providing advice and expertise that empowers biotech, med device, and pharmaceutical organizations of all sizes to confidently advance scientific breakthroughs and introduce new therapies. As the world’s largest RCO (Research Consulting Organization), ProPharma partners with its clients through an advise-build-operate model across the complete product lifecycle. With deep domain expertise in regulatory sciences, clinical research solutions, quality & compliance, pharmacovigilance, medical information, and R&D technology, ProPharma offers an end-to-end suite of fully customizable consulting solutions that de-risk and accelerate our partners’ most high-profile drug and device programs.